Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Google Disrupts Major Residential Proxy Network IPIDEA 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
NEW YORK, May 23, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular Therapeutics") (NYSEMKT:IMUC) securities between May 1, 2012 and December 11, 2013.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/immunocellular-therapeutics-ltd?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; (2) as a result of this scheme, the market was led to believe that ImmunoCellular's clinical studies for its product candidate ICT-107 was going well and the Company's share price was artificially inflated.
On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, that had engaged in stock promotion schemes.
If you suffered a loss in ImmunoCellular Therapeutics you have until June 30, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/immunocellular-therapeutics-ltd?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
